Ann Fonfa posted this to the Project LEAD listserv immediately after Dr. Sporn's talk. Heard several strong talks on chemoprevention using triterpenoids,rexinoids and SERMS together. Michael Sporn of Dartmouth suggested that the advocacy community is not focused on chemoprevention. I offered to work in concert with him to discuss the issues. I suggested that if chemoprevention (using the LEAST toxic choices) was directed toward secondary prevention - that's us folks - it would be well received. He had complained that the pharmaceutical industry was ignoring the issue being focused on lucrative treatment areas, from fear of liability, and potential patent problems. He also suggested FDA issues of regulatory difficulties in combining substances, and with endpoints/surrogate markers. And, insurance companies are not currently covering chemoprevention at all. However, back to Sporn's discussion of triterpenoids/SERMS and rexinoids. His chart showed that the combination of Arzoxifene and LG100268, in MICE, yielded NO tumor growth. Used MMT-neu mice. Although this study was in mice, his lab has been characterizing the triterpenoids/rexinoids for many years. He believes it is ready to move into human trials. Another combo that yielded very good results was CDDO-me and LG100268 (triterpenoid and rexinoid) - he showed, again in mice looking at lung carcinogenesis - that the control animals had 8X more tumors and tumor volume was 35-70 X larger. Also only one high-grade tumor in treated animals versus 40 in 20 mice in controls. The future? Frontiers in Cancer Prevention Research, 2006 Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.